ReviewMolecular biology reports2021
An updated review on the role of the CXCL8-CXCR1/2 axis in the progression and metastasis of breast cancer.
Review in Molecular biology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Impacts of Chemokine (C-X-C Motif) Receptor 2 C1208T Polymorphism on Cancer Susceptibility.Journal of immunology research · 2021Pooled it
- [Parecoxib sodium down-regulates CXCL8-CXCR1/2 to improve inflammatory microenvironment and promote patient recovery following laparoscopic radical resection of rectal cancer].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Trial
- M196R-TNFR2 and membrane TNFα down-regulate soluble TNFα-induced pro-metastatic functions in triple-negative breast cancer cells.Cancer cell international · 2026Article
- PD-L1 and PD-L2 regulate in cell-autonomous and N-glycosylation-dependent manners the pro-tumorigenic characteristics and functions of human cancer-associated fibroblasts.Molecular medicine (Cambridge, Mass.) · 2026Article
- Pro-Apoptotic and Anti-EMT Activity of Wild Ginseng Adventitious Root Extract in MDA-MB-231 TNBC Cells: Association with GSK-3β/β-Catenin Signaling.Pharmaceuticals (Basel, Switzerland) · 2026Article
- CMSS1 promoted CXCL8-CXCR1/2 pathway to accelerate the invasion and immune escape of triple-negative breast cancer.Journal of molecular histology · 2026Article
- Unlocking the Power of CXCR2 Inhibition to Overcome Gemcitabine Resistance in Pancreatic Cancer.FASEB bioAdvances · 2026Article
- Acetyl-CoA carboxylase 1 knockdown promotes esophageal squamous cell carcinoma metastasis via the CXCL8-NET axis.Communications biology · 2025Article
- Serum CXCL8 as a biomarker for predicting ALNM in breast cancer: Combined diagnostic value with tumor markers and ultrasound.Journal of medical biochemistry · 2025Article
- Prognostic analysis and immunotherapy prediction based on key receptor-ligand pairs of bladder cancer.Discover oncology · 2025Article
- Disruption of ARID1B Recruitment to the Nuclear Pore Complex as a New Anticancer Therapeutic Strategy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Single-cell sequencing analysis reveals the promotion of ELR CXCL genes on angiogenesis and the influence on malignant progression in glioblastoma.Journal of clinical biochemistry and nutrition · 2025Article
- BALF editome profiling reveals A-to-I RNA editing associated with severity and complications ofmSphere · 2025Article
- Myeloid cells are involved in tumor immunity, metastasis and metabolism in tumor microenvironment.Cell biology and toxicology · 2025Review
- High CXCL8 expression predicting poor prognosis in triple-negative breast cancer.Anti-cancer drugs · 2025Article
- Prognostic values of intracellular cell-related genes in esophageal cancer and their regulatory mechanisms.BMC cancer · 2025Article
- CXCR1 and CXCR2 Antagonism with G31P Attenuates Chemotherapy-Induced Lung Inflammation and Augments the Gefitinib Therapeutic Response in Lung Cancer.Oncology research · 2025Article
- Article
- Chemokines: humble yet mighty players in the tumour microenvironment.Frontiers in immunology · 2025Review
- The power of many: Multilevel targeting of representative chemokine and metabolite GPCRs in personalized cancer therapy.European journal of immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic inflammation is a major factor in tumor growth and progression. Cancer cells secrete C-X-C chemokine ligand 8 (CXCL8) along with its receptor C-X-C chemokine receptor 1 (CXCR1) and chemokine receptor 2 (CXCR2). It plays a significant role in the activation and trafficking of inflammatory mediators, tumor proliferation and interferes in breast cancer development by controlling cell adhesion, proliferation, migration, and metastasis. This axis also plays a significant role in driving different cancers and melanomas, including breast cancer progression, by controlling stem cell masses. Few small-molecule CXCR1/2 inhibitors and CXCL8 releasing inhibitors have been identified in the past two decades that bind these receptors in their inactive forms and blocks their signaling as well as the biological activities associated with inflammation. Inhibitors of certain inflammatory molecules are projected to be more efficient in different inflammatory diseases. Preclinical trials indicate that patients may be benefitted from combined treatment with targeted drugs, chemotherapies, and immunotherapies. Thus, targeting the CXCL8-CXCR1/2 signaling axis in breast cancer could be a promising approach for its therapeutics. This review examines the roles of the CXCL8-CXCR1/2 signaling axis and how it is implicated in the tumor microenvironment in breast cancer. In addition, we also discuss the potential role of the CXCL8-CXCR1/2 axis in targeted therapeutics for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.